Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Coya Therapeutics, Inc. - Common Stock (NQ: COYA )

4.340 +0.140 (+3.33%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Coya Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
Why Bluejay Diagnostics Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket
Gainers Visionary Education Technology Holdings Group Inc. (NASDAQ: VEDU) shares rose 85.8% to $0.7985 in pre-market trading. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time for another dive into the latest pre-market stock movers as we check out all of the news moving shares on Tuesday morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023
 
Via Benzinga
Tesla, Manchester United, Ohmyhome, Target, Coya: Why These 5 Stocks Are Drawing Investor Attention Today
 
Via Benzinga
Coya Therapeutics: Another Sucess
The Coya story is just beginning and as the company expands with larger trials, the success in those trials will only increase the valuation of the company. 
Via Talk Markets
Why Coya Therapeutics Shares Are Shooting Higher Today
Coya Therapeutics Inc (NASDAQ: COYA) reported results from an open-label proof-of-concept clinical study for COYA 301 in  
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Positive Financials Along With Promising Clinical Results – Coya Therapeutics
Howard Berman, Ph.D., CEO & Chairman of the Board of Coya Therapeutics, Inc. (NASDAQ: COYA), was recently a guest on Benzinga’s All Access. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2023
 
Via Benzinga
Coya Therapeutics Reveals Proof-of-Concept Data From Small Study With ALS Patients
 
Via Benzinga
Coya Therapeutics: An Attractive Valuation And First Set Of Data
Coya recent data in ALS seems under appreciated by the market and upcoming data in Alzheimer's offers the opportunity to confirm the early signals of efficacy in neurological conditions. 
Via Talk Markets
Alzheimer's Disease Largely Remains A Mystery, With A Lack Of Highly Effective Treatments — Could Regulatory T-Cells (Tregs) Be The Answer?
In many ways, Alzheimer's disease (AD) remains a mystery. Most common in those over 65, AD is the most common form of dementia, but its exact causes remain unclear, and treatments are unable to halt or... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
There Is No Cure For ALS, But Coya Therapeutics Might Have The Answer According To A New Clinical Study
There Is No Cure For ALS, But Coya Therapeutics Might Have The Answer According To A New Clinical Study 
Via News Direct
There Is No Cure For ALS, But Coya Therapeutics Might Have The Answer According To A New Clinical Study
Coya Therapeutics (NASDAQ: COYA) has just reported proof of concept data from its trial for COYA 302, a new combination drug for treating amyotrophic lateral sclerosis (ALS). 
Via Benzinga
Coya Therapeutics: This BioPharma Company Has Some Big News To Share
Howard Burman, Ph.D, CEO & Chairman of Coya Therapeutics Inc (NASDAQ: COYA), was a guest on Benzinga’s All Access. 
Via Benzinga
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development 
Via News Direct
Coya Therapeutics’ COYA 302 Treating ALS Proves Effective In Proof-Of-Concept Academic Clinical Study
Coya Therapeutics’ COYA 302 Treating ALS Proves Effective In Proof-Of-Concept Academic Clinical Study 
Via News Direct
Topics Death
Exposures Death
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is A Major Moment For Drug Development
Houston-based Coya Therapeutics (NASDAQ: COYA) has entered into a partnership with Dr. Reddy’s Laboratories Ltd. (NYSE: RDY), a world-leading pharmaceutical company based in India. 
Via Benzinga
Coya Therapeutics' COYA 302 Treating ALS Proves Effective In Proof-Of-Concept Academic Clinical Study
Coya Therapeutics, Inc. (NASDAQ: COYA) recently reported 48-week clinical data for its proof-of-concept open-label study in 4 ALS patients indicating that treatment with COYA 302 appeared to... 
Via Benzinga
Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302
Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302 
Via News Direct
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy's Laboratories To License And Commercialize COYA 302
Coya Therapeutics, Inc. (NASDAQ: COYA) recently announced a worldwide agreement with Dr. Reddy’s Laboratories Limited. 
Via Benzinga
This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine’s Next Frontier?
This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine’s Next Frontier? 
Via News Direct
This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine's Next Frontier?
Texas-based biotech company, Coya Therapeutics (NASDAQ: COYA), is positioning itself as a leader in a promising area of the medical field. 
Via Benzinga
Houston-Based Coya Therapeutics To Present Results From ALS Clinical Study Data For Its Investigational Biologic Combination at the 2023 MDA Clinical & Scientific Conference in Dallas
Houston-Based Coya Therapeutics To Present Results From ALS Clinical Study Data For Its Investigational Biologic Combination at the 2023 MDA Clinical & Scientific Conference in Dallas 
Via News Direct
Houston-Based Coya Therapeutics To Present Results From ALS Clinical Study Data For Its Investigational Biologic Combination at the 2023 MDA Clinical & Scientific Conference in Dallas
Coya Therapeutics, Inc. (NASDAQ: COYA) recently announced the presentation of results from an academic clinical study in patients with Amyotrophic Lateral Sclerosis (ALS) with Coya’s proprietary... 
Via Benzinga
Coya Therapeutics’ Expansion Of Exclusive Worldwide Licensing Agreement With ARscience Biotherapeutics Could Have Outsized Impact On Neurodegenerative And Autoimmune Diseases Treatments
Coya Therapeutics’ Expansion Of Exclusive Worldwide Licensing Agreement With ARscience Biotherapeutics Could Have Outsized Impact On Neurodegenerative And Autoimmune Diseases Treatments 
Via News Direct
Coya Therapeutics' Expansion Of Exclusive Worldwide Licensing Agreement With ARscience Biotherapeutics Could Have Outsized Impact On Neurodegenerative And Autoimmune Diseases Treatments
Houston, Texas-based Coya Therapeutics Inc. (NASDAQ: COYA) has just taken a giant leap in making effective proprietary treatments focused on certain neurodegenerative and autoimmune diseases available... 
Via Benzinga
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.